Evaluation of: Bush J, Duncan JA, Bond JS et al. Scar-improving efficacy of avotermin administered into the wound margins of skin incisions evaluated by a randomized, double-blind, placebo-controlled, Phase II clinical trial. Plast. Reconstr. Surg. 126(5), 1604--1615 (2010).Scar formation is a medical problem that affects a diverse population of patients, at times leading to devastating physical
... [Show full abstract] and psychological consequences. In contrast to adult skin, early gestational fetal skin heals without scar formation. This discovery has led to a large field of research related to defining the factors responsible for scarless wound healing. The TGF-ββ superfamily has been a major focus for the field of regenerative medicine, as its three mammalian isoforms exhibit varying degrees of activity between fetal and adult skin. Avotermin is a novel human recombinant TGF-ββ3 protein that has been studied both in vitro and in vivo for its antiscarring properties. This article evaluates a recently published Phase II clinical trial focused on the role of avotermin as a prophylactically administered, scar-reducing biologic agent for the treatment of human incisional wounds.